Numerous epidemiological studies have been performed to determine factors that might contribute to the development of inflammatory bowel disease. Although the role oforal contraceptive agents in Crohn's disease (CD) and ulcerative colitis (UC) have been assessed, most studies were of small sample size and characterised by low statistical precision. A meta-analysis was performed to increase the statistical power and to investigate the association between the use of oral contraceptives and the development of CD and UC. The study was based on a search of a Medline database from 1975 to October 1993 and a review of reference lists from published articles, reviews, symposia proceedings, and abstracts from major gastrointestinal meetings. All studies specifically designed to evaluate this association were selected. The combined results of nine studies -two cohort studies (30 379 unexposed and 30 673 exposed patients) and seven case-control studies (482 CD, 237 UC, and 3198 controls) -which satisfied our selection criteria were evaluated. The pooled relative risk (adjusted for smoking) associated with oral contraceptive use was 1.44 (1.12, 1.86) for CD and 1.29 (0.94, 1.77) for UC. These results suggest modest associations between the use of oral contraceptives and the development of CD and UC. As these associations are weak, non-causal explanations for the findings cannot be eliminated. (Gut 1995; 37: 668-673) 
Recent epidemiological studies have assessed the role of oral contraceptives in CD or UC, or both. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] Most of these studies, however, were of small sample size and characterised by low statistical power. We therefore performed a meta-analysis to increase the statistical power to address this important clinical question. Our primary objective was to investigate the association between the use of oral contraceptives and the development of CD and UC.
Methods
We performed a meta-analysis, based on a search in English and French language using a Medline database under the list terms 'Crohn's disease', 'ulcerative colitis', or 'inflammatory bowel disease' and 'oral contraceptive agents' from 1975 to 1993. We also reviewed reference lists from published articles, reviews, symposia proceedings, and abstracts from major gastrointestinal meetings. We selected all casecontrol and cohort studies specifically designed to evaluate this association. An acceptable comparison group had to be formed by either a non-user population (cohort studies) or by inpatients, outpatients, or neighbours of the cases (case-control studies). The identification of women as never, ever, or current users was not required for this analysis, although most of the studies provided this information. No restrictions were imposed for the method by which information was obtained (by mail, phone, or interview in all studies) or the number of subjects in Although we combined the results from cohort and case-control studies when possible, we evaluated separately the effect of oral contraceptives for CD and UC. We distinguished between studies that were adjusted for smoking and those which were not. Although the results will be reported separately for subgroups, we tested for homogeneity29 for each subgroup. Potentially, heterogeneity may result when results from studies giving rates adjusted only for smoking are combined with studies adjusted for smoking, diet, and education. The statistical tests for homogeneity gave p values greater than 0.30 for CD studies adjusted for smoking, for CD studies unadjusted for smoking, and for UC studies adjusted for smoking. We thus assumed that existing heterogeneity between studies was small enough to be reasonably ignored. Homogeneity has not been tested for the two UC studies unadjusted for smoking because the value of the pooled risk estimate was unclear.
We recalculated the RRs whenever raw data were provided. None of the recalculated estimates differed appreciably from those reported in the original research. Table I shows a summary of the characteristics of excluded studies. Two studies13 14 In general, the reported estimates of an association between the use of oral contraceptives and either CD or UC are remarkably consistent in terms of the direction of the findings -an increased RR of CD and UC in oral (27) Sandier (21) Lashner (24) Pooled RR
Results

EXCLUDED STUDIES
B
Persson (25) Calkins (20) Pooled RR 
No data on those lost to follow up. RR for CD adjusted for smoking: 1.51 (0.75, 3.05), ever smokers v never smokers.
RR for UC adjusted for smoking: 1-44 (0-85, 2 45), ever smokers v never smokers.
Comments: all RRs fell short of statistical significance, although the trend suggests a modest association for both diseases. Former users did not have an increased risk for both diseases oral contraceptive use was defined as continuous use for more than six months before beginning of symptoms. Smoking was assessed only at recruitment.
2 Case-control studies 2.1 Lesko 1985.23 Prospective study from several North American cities examining primarily the association between oral contraceptive use and inflammatory bowel disease.
Cases: 57 inpatients with CD (84% severe), 82% diagnosed with 3 months of interview.
Controls: 2189 inpatients with infection, trauma.
Excluded: gastrointestinal infection, pelvic inflammatory disease, UC.
RR estimate given by the author: 1.7 (10, 3.2); adjusted for age, race, religion, education, cigarette use, year of interview, geographic region, number of previous admissions.
Comments: data are not adequate to study smoking interaction. The study suggests that former oral contraceptive users are not at increased risk. There is a positive trend but not a significant association between duration of oral contraceptive use and RR (p=027). There is a negative trend but not a significant association between time elapsed since last oral contraceptive use and RR. Patients take oral contraceptive for different purposes (contraception, menstrual problems, sexual difficulties, endometriosis, and infertility). Forty two per cent of cases and 51% of controls were 40 years old or over and four per cent refused. Comments: the OR estimates given by the author for the possible confounding effect of smoking computed with three different conditional regression models for the duration of use are not different from 1. Authors conclude there is no evidence that oral contraceptive are a risk factor for either diseases because: (1) overall OR is not different from unity, (2) there is no association demonstrated by stratifying the data, and (3) there is no dose response effect. These studies are externally validated by the finding of a positive and a negative associations for smoking on one hand and CD and UC, respectively, on the other. Studies did not show an interaction or a confounding effect between oral contraceptive use and smoking. The minimal OR for oral contraceptive use if statistical significance is achieved (ot error of 5%, C error of 20%) is around 2-8 for both studies. 2.5 Katschinski 1993.27 Retrospective and prospective study from Essen, Germany; examining an association between CD and oral contraceptive use and smoking.
Cases: 90 outpatients attending clinic from 1986-88, among whom 61% were aged <25 years at disease onset.
Controls: 90 matched for age and randomly selected among city population.
Excluded: women with hysterectomy or those unable to take oral contraceptive.
RR given by the author: 2 5 (1I6, 6 6) adjusted for smoking.
Comments: this study gives evidence of an association between oral contraceptive use and CD only for non-smokers. There is no evidence of a duration effect or a preferential site (non-significant trend toward ileal CD in oral contraceptive users). The study shows clearly an interaction effect of smoking and oral contraceptive use in inflammatory bowel disease. Eighty to 88% responded to the questionnaire. 
